Brought to you by 
Silence buys fellow RNAi firm Intradigm
04 Jan 2010
Executive Summary
Bringing together their capabilities in RNA interference, Silence Therapeutics PLC has acquired privately held Intradigm for £18.3mm ($29.5mm) in stock.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Silence buys fellow RNAi firm Intradigm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice